Genmab — Juli 2020
-
GBR1342 cd3xcd38 is still alive https://www.clinicaltrials.gov/ct2/show/NCT03309111?term=gbr1342&draw=2&rank=1
-
USD sales will give a lower revenue in DKK. There is a partial natural hedge due to costs made in the US, eg with the US office or trial costs. On the other hand it will raise USD sales number for Daratumumab sales in Europe, thereby increasing the Dara royalty revenue amount (in USD
) -
Servicemeddelelse: Tjek menulinjen ud.
-
God morgen.
-
Genmab/Nordea omtale efter 4 minutter.
-
-
-
Tak Sukker.
-
Følg Proinvestor på Twitter: https://twitter.com/Proinvestor_com
-
Sanofi Q2 2020 earnings transcript (masser af info om Sarclisa) https://www.google.com/amp/s/seekingalpha.com/amp/article/4362034-sanofis-sny-ceo-paul-hudson-on-q2-2020-results-earnings-call-transcript
-
CEO states that so far no evidence that CD38 could have a broad role in either solid tumors or other hematologic malignancies
-
Tak GB..Det er vel der vi står.
-
Ja, de kommer til samme konklusion som Janssen vedr.
CD38 virkning i solide -
Netop.
-
Hvis den falder 30-40 kr pr. dag indtil 12. aug kommer den godt nok skræmmende langt ned.
Hello! It looks like you're interested in this conversation, but you don't have an account yet.
Getting fed up of having to scroll through the same posts each visit? When you register for an account, you'll always come back to exactly where you were before, and choose to be notified of new replies (either via email, or push notification). You'll also be able to save bookmarks and upvote posts to show your appreciation to other community members.
With your input, this post could be even better 💗
Tilmeld Log ind